ModernGraham Valuation

Company Name:

Company Ticker ABC Date of Analysis

Corp.

AmerisourceBergen



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

4/5/2018

Defensive Inv t of the following 7 f

Delensive investor, in	ust pass 6 out of the following 7 tests.			
	1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$18,678,378,621	Pass
	2. Sufficiently Strong Financial Condition	Current Ratio > 2	0.95	Fail
	3. Earnings Stability	Positive EPS for 10 years prior		Fail
	4. Dividend Record	Dividend Payments for 10 years prior		Pass
		Increase of 33% in EPS in past 10		
	5. Earnings Growth	years using 3 year averages at beginning and end	124.45%	Pass
	6. Moderate PEmg Ratio	PEmg < 20	22.73	
	7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	6.71	Fail
Enterprising Investor;	must pass 4 out of the following 5 tests, or be	suitable for the Defensive Investor.		
	1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.95	Fail
	2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-2.96	Fail
	3. Earnings Stability	Positive EPS for 5 years prior		Fail
	4. Dividend Record	Currently Pays Dividend		Pass
	5. Earnings Growth	EPSmg greater than 5 years ago		Pass
		Score		
Suitability				
	Defensive	No		
	Enterprising	Νο		
Ctore 2. Deter	mination of Intrinaia Value			
Stage 2: Deter	mination of Intrinsic Value			
Stage 2: Deter	EPSmg	\$3.84		
Stage 2: Deter	EPSmg MG Growth Estimate	14.97%		
Stage 2: Deter	EPSmg MG Growth Estimate MG Value	14.97% \$147.82		
Stage 2: Deter	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth	14.97% \$147.82 \$55.75		
Stage 2: Deter	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth	14.97% \$147.82 \$55.75 \$32.68		
	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth	14.97% \$147.82 \$55.75		
Stage 2: Deter	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate	14.97% \$147.82 \$55.75 \$32.68 7.11%		
	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price	14.97% \$147.82 \$55.75 \$32.68 7.11% \$87.38		
	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value	14.97% \$147.82 \$55.75 \$32.68 7.11% \$87.38 59.11%		
	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value Opinion	14.97% \$147.82 \$55.75 \$32.68 7.11% \$87.38 59.11% Undervalued		
	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value	14.97% \$147.82 \$55.75 \$32.68 7.11% \$87.38 59.11%		
MG Opinion	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value Opinion MG Grade	14.97% \$147.82 \$55.75 \$32.68 7.11% \$87.38 59.11% Undervalued		
MG Opinion	EPSmg MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value Opinion	14.97% \$147.82 \$55.75 \$32.68 7.11% \$87.38 59.11% Undervalued		


Net Current Asset Value (NCAV)	-\$37.09
Graham Number	\$37.07
PEmg	22.73
Current Ratio	0.95
PB Ratio	6.71
Current Dividend	\$1.46
Dividend Yield	1.67%
Number of Consecutive Years of Dividend	
Growth	12


Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus

Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	\$6.45	Next Fiscal Year Estimate	\$3.84
Sep2017	\$1.64	Sep2017	\$2.38
Sep2016	\$6.32	Sep2016	\$2.60
Sep2015	-\$0.63	Sep2015	\$1.01
Sep2014	\$1.16	Sep2014	\$1.92
Sep2013	\$1.84	Sep2013	\$2.27
Sep2012	\$2.80	Sep2012	\$2.33
Sep2011	\$2.54	Sep2011	\$1.96
Sep2010	\$2.22	Sep2010	\$1.58
Sep2009	\$1.66	Sep2009	\$1.20
Sep2008	\$0.77	Sep2008	\$0.9
Sep2007	\$1.25	Sep2007	\$1.04
Sep2006	\$1.13	Sep2006	\$0.93
Sep2005	\$0.62	Sep2005	\$0.8
Sep2004	\$1.02	Sep2004	\$0.86
Sep2003	\$0.98	Sep2003	\$0.73
Sep2002	\$0.79	Sep2002	\$0.56
Sep2001	\$0.53	Balance Sheet Information	12/1/2017
Sep2000	\$0.48	Total Current Assets	\$25,296,432,000
Sep1999	\$0.33	Total Current Liabilities	\$26,740,291,000
Sep1998	\$0.21	Long-Term Debt	\$4,266,757,000
		Total Assets	\$36,361,510,000
		Intangible Assets	\$8,901,145,000
		Total Liabilities	\$33,486,928,000
		Shares Outstanding (Diluted Average)	220,822,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other	27 Companies in the Spotlight This Week - 4/4/15
ModernGraham posts about the company	AmerisourceBergen Corporation Annual Valuation – 2015 \$ABC
	14 Companies in the Spotlight This Week - 4/5/14
	Amerisource Bergen (ABC) Annual Valuation – 2014
	14 Companies in the Spotlight This Week – 1/4/14
Other ModernGraham posts about related	AbbVie Inc Valuation – April 2018 \$ABBV
	Eli Lilly and Co. Valuation – March 2018 \$LLY
companies	Zoetis Inc Valuation – March 2018 \$ZTS
	Gilead Sciences Inc Valuation – March 2018 \$GILD
	Pfizer Inc Valuation – February 2018 \$PFE
	Merck & Co Inc Valuation – February 2018 \$MRK
	Johnson & Johnson Valuation – February 2018 \$JNJ
	Bristol-Myers Squibb Co Valuation – September 2017 \$BMY

Momenta Pharmaceuticals Inc Valuation - Initial Coverage \$MNTA

Depomed Inc Valuation - Initial Coverage \$DEPO